These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 3681191)

  • 41. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines.
    Keitel WA; Bond NL; Zahradnik JM; Cramton TA; Robbins JB
    Vaccine; 1994; 12(3):195-9. PubMed ID: 8165850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM
    Micoli F; Bjarnarson SP; Arcuri M; Aradottir Pind AA; Magnusdottir GJ; Necchi F; Di Benedetto R; Carducci M; Schiavo F; Giannelli C; Pisoni I; Martin LB; Del Giudice G; MacLennan CA; Rappuoli R; Jonsdottir I; Saul A
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24443-24449. PubMed ID: 32900928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa.
    Arya SC
    Vaccine; 1997 Feb; 15(2):244. PubMed ID: 9066045
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines.
    Tritama E; Riani C; Rudiansyah I; Hidayat A; Kharisnaeni SA; Retnoningrum DS
    Hum Vaccin Immunother; 2018 Jun; 14(6):1524-1529. PubMed ID: 29359991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines.
    Alugupalli KR
    Front Immunol; 2024; 15():1383476. PubMed ID: 38799439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.
    Pakkanen SH; Kantele JM; Rombo L; Kantele A
    Scand J Immunol; 2017 Oct; 86(4):207-215. PubMed ID: 28675263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi.
    Rondini S; Micoli F; Lanzilao L; Pisoni I; Di Cioccio V; Saul AJ; Martin LB
    J Infect Dev Ctries; 2012 Nov; 6(11):763-73. PubMed ID: 23277501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
    Micoli F; Rondini S; Pisoni I; Proietti D; Berti F; Costantino P; Rappuoli R; Szu S; Saul A; Martin LB
    Vaccine; 2011 Jan; 29(4):712-20. PubMed ID: 21115057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
    Meena J; Kumar R; Singh M; Ahmed A; Panda AK
    Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A chemical typhoid vaccine containing a surface-antigen complex including the K-antigen].
    Stepanova LK; Belaia IuA; Sergeeva NS; Ageeva VA; Petrukhin VG
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (1):51-6. PubMed ID: 7520650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.
    Marshall JL; Flores-Langarica A; Kingsley RA; Hitchcock JR; Ross EA; López-Macías C; Lakey J; Martin LB; Toellner KM; MacLennan CA; MacLennan IC; Henderson IR; Dougan G; Cunningham AF
    J Immunol; 2012 Dec; 189(12):5527-32. PubMed ID: 23162127
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
    Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
    Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
    Honda-Okubo Y; Cartee RT; Thanawastien A; Seung Yang J; Killeen KP; Petrovsky N
    Vaccine; 2022 Jul; 40(32):4625-4634. PubMed ID: 35750538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever.
    Stone AL; Szu SC
    J Clin Microbiol; 1988 Apr; 26(4):719-25. PubMed ID: 3366868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
    Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vi capsular polysaccharide: Synthesis, virulence, and application.
    Hu X; Chen Z; Xiong K; Wang J; Rao X; Cong Y
    Crit Rev Microbiol; 2017 Aug; 43(4):440-452. PubMed ID: 27869515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
    Pulickal AS; Pollard AJ
    Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
    [No Abstract]   [Full Text] [Related]  

  • 60. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
    Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
    Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.